Ordering Recommendation
Consider ordering for individuals with paraneoplastic encephalomyelitis, chorea, cerebellar degeneration, optic neuritis, and peripheral neuropathy. May aid in diagnosis of occult or recurrent tumor.
Mnemonic
Methodology
Semi-Quantitative Cell-Based Indirect Fluorescent Antibody
Performed
Thu
Reported
1-8 days
New York DOH Approval Status
Specimen Required
Serum Separator Tube (SST) or Plain Red
Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.25 mL)
Refrigerated
Hemolyzed, contaminated, or severely lipemic specimens
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year
Reference Interval
Test Number |
Components |
Reference Interval |
---|---|---|
CV2.1 Antibody IgG Screen by IFA | Less than 1:10 |
Interpretive Data
CV2.1 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2.1 is associated with small-cell lung cancer and thymoma.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
Note
If CV2.1 Antibody IgG Screen by IFA is positive, then CV2.1 Antibody IgG Titer by IFA will be added. Additional charges apply.
Hotline History
Hotline History
CPT Codes
86255; if reflexed, add 86256
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
2013959 | CV2.1 Antibody IgG Screen by IFA | 72504-4 |
Aliases
- Cerebellar degeneration
- Chorea
- Collapsin response-mediator protein 5
- Cranial neuropathy
- CRMP5
- CV2
- Myelopathy
- Peripheral neuropathy
- Vision loss